Endologix Cuts FY17 Guidance, GAAP EPS from $(0.95) to $(0.91) to $(0.93) to $(0.91) vs $(0.62) Est., Sales from $185M-$190M to $181M-$184M vs $187.33M Est., Citing Slower Than Expected AFX2 Sales Recovery In The U.S.